Wednesday, July 8, 2026

pharma · Relapsed/Refractory Diffuse Large B-cell Lymphoma · Non-muscle invasive bladder cancer (NMIBC)

Shanghai Antengene Corporation

Shanghai Antengene Corporation clinical programs — 1 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

SAINT-LAURENT, CN HQ
NMPA registrant Type
Company details
Intelligence · Clinical Programs

Shanghai Antengene Corporation projects

1 ClinicalTrials.gov programs sponsored by Shanghai Antengene Corporation.

Shanghai Antengene Corporation has 1 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. ATG-010 and ATG-008

    Shanghai Antengene Corporation Limited

    Relapsed/Refractory Diffuse Large B-cell Lymphoma

    phase 1 other terminated

    1 trial

Frequently asked questions

How many clinical projects does Shanghai Antengene Corporation have?

1 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.